[go: up one dir, main page]

WO2002043566A3 - Dispositifs et methodes permettant de traiter des taux de glycemie bas - Google Patents

Dispositifs et methodes permettant de traiter des taux de glycemie bas Download PDF

Info

Publication number
WO2002043566A3
WO2002043566A3 PCT/US2001/044552 US0144552W WO0243566A3 WO 2002043566 A3 WO2002043566 A3 WO 2002043566A3 US 0144552 W US0144552 W US 0144552W WO 0243566 A3 WO0243566 A3 WO 0243566A3
Authority
WO
WIPO (PCT)
Prior art keywords
subject
source
area
intact skin
devices
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/044552
Other languages
English (en)
Other versions
WO2002043566A2 (fr
Inventor
Martin G Baum
Roger T Putman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to AU2002230509A priority Critical patent/AU2002230509A1/en
Publication of WO2002043566A2 publication Critical patent/WO2002043566A2/fr
Publication of WO2002043566A3 publication Critical patent/WO2002043566A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concernent des méthodes et des dispositifs utilisés pour maintenir l'apparition de taux de glycémie en dessous d'un taux minimum prédéterminé pendant un laps de temps prolongé. Cette invention concerne des méthodes et des dispositifs permettant de produire un effet thérapeutique chez un sujet. Ces méthodes et ces dispositifs consistent à placer une source de glucose ou de glucagon dans un timbre transdermique sur une zone de peau intacte de manière à faire pénétrer le glucose ou le glucagon dans la zone de peau intacte; puis à administrer le glucose ou le glucagon au sujet depuis la source et à travers la zone de peau intacte pendant un laps de temps prolongé, à un taux thérapeutiquement efficace durant une grande partie du laps de temps, de manière à empêcher l'apparition d'un taux de glycémie bas chez un sujet. Les méthodes et les dispositifs décrits dans cette invention permettent d'administrer le glucose ou le glucagon à un sujet depuis la source et à travers la zone de peau intacte pendant au moins 4 heures, peut-être 24 heures ou plus. Ces méthodes et ces dispositifs conviennent particulièrement à l'administration du glucose ou du glucagon à un sujet depuis la source et à travers la zone de peau intacte entre les heures habituelles de sommeil. Des substances thérapeutiques supplémentaires, parmi lesquelles un ou plusieurs compléments nutritionnels tels que les vitamines A, C, ou D, peuvent également être administrées au sujet.
PCT/US2001/044552 2000-11-28 2001-11-28 Dispositifs et methodes permettant de traiter des taux de glycemie bas Ceased WO2002043566A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002230509A AU2002230509A1 (en) 2000-11-28 2001-11-28 Devices and methods for treating low blood sugar levels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72383700A 2000-11-28 2000-11-28
US09/723,837 2000-11-28

Publications (2)

Publication Number Publication Date
WO2002043566A2 WO2002043566A2 (fr) 2002-06-06
WO2002043566A3 true WO2002043566A3 (fr) 2002-09-26

Family

ID=24907892

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/044552 Ceased WO2002043566A2 (fr) 2000-11-28 2001-11-28 Dispositifs et methodes permettant de traiter des taux de glycemie bas

Country Status (2)

Country Link
AU (1) AU2002230509A1 (fr)
WO (1) WO2002043566A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655618B2 (en) 2002-12-27 2010-02-02 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
WO2004060387A1 (fr) 2002-12-27 2004-07-22 Diobex, Inc. Compositions et procedes de prevention et reduction de l'hypoglycemie induite par l'insuline
US7591801B2 (en) 2004-02-26 2009-09-22 Dexcom, Inc. Integrated delivery device for continuous glucose sensor
EP4098177A1 (fr) 2007-10-09 2022-12-07 DexCom, Inc. Système d'administration d'insuline intégré avec un capteur de glucose en continu
AU2008316630A1 (en) 2007-10-25 2009-04-30 Dexcom, Inc. Systems and methods for processing sensor data

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5360614A (en) * 1993-04-26 1994-11-01 The Estee Corporation Method of controlling the release of carbohydrates by encapsulation and composition therefor
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5234906A (en) * 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
US5360614A (en) * 1993-04-26 1994-11-01 The Estee Corporation Method of controlling the release of carbohydrates by encapsulation and composition therefor
US5707641A (en) * 1994-10-13 1998-01-13 Pharmaderm Research & Development Ltd. Formulations comprising therapeutically-active proteins or polypeptides
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides

Also Published As

Publication number Publication date
WO2002043566A2 (fr) 2002-06-06
AU2002230509A1 (en) 2002-06-11

Similar Documents

Publication Publication Date Title
IL135712A0 (en) Methods for treating hypercoagulable states or acquired protein c deficiency
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
JP2003521528A5 (fr)
DE60222137D1 (de) Zuckerderivate von hydromorphon, dihydromorphin und dihydroisomorphin, zusammensetzungen davon und verwendung zur vorbeugung und behandlung von schmerzen
WO2004052284A3 (fr) Traitement de diabetes
IL208184A0 (en) Glp-1, and methods for treating diabetes
MXPA03006217A (es) Sistema de administracion espaciada de farmacos.
MXPA05006994A (es) Composiciones y metodos para la prevencion y el control de hipoglucemia inducida por insulina.
WO2003089033A8 (fr) Systeme d'administration de medicament implantable sensible a la pression intracardiaque
WO2002070473A3 (fr) Derives de carboxamide utilises comme agents therapeutiques
WO2003092617A3 (fr) Combinaisons destinees au traitement de troubles cutanes inflammatoires
WO2002060410A3 (fr) Methodes d'administration locale a liberation prolongee de medicaments visant a l'ablation de tissus non desires
WO2004010946A3 (fr) Traitement therapeutique pour le syndrome metabolique et les diabetes de type 2
WO2002043566A3 (fr) Dispositifs et methodes permettant de traiter des taux de glycemie bas
WO2002005801A3 (fr) Compositions pharmaceutiques et procedes d'utilisation de ces dernieres
AU3308099A (en) Method for the treatment of pain, including chronic and female specific pain
WO2005087255A3 (fr) Procede d'optimisation de traitement avec l'interferon -tau
WO2000059940A3 (fr) Gene et proteine lies au facteur de croissance d'origine plaquettaire
EP1033133A4 (fr) Composition pour le traitement du diabete et procede de traitement du diabete
WO2001028578A3 (fr) Composition pharmaceutique a base de pglu-glu-pro-nh2 et procede de traitement de maladies et de lesions cerebrales
ATE207353T1 (de) Verwendung von benzydamin zur behandlung von krankheitszuständen, die durch tnf verursacht werden
CA2405265A1 (fr) Procede de prevention ou de traitement du diabete
AU2003259006A1 (en) Composition and method for use in intestinal cleansing procedures
Diukova et al. Treatment of autonomic crises (attacks of panic)
SSADOVSKY Algorithm for subcutaneous heparin treatment of DVT.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP